Genmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by TD Cowen

Genmab A/S (NASDAQ:GMAB) was upgraded by investment analysts at TD Cowen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, Marketbeat Ratings reports. The firm presently has a $43.00 price objective on the stock, up from their previous price objective of $32.00. TD Cowen’s target price indicates a potential upside of 47.41% from the stock’s current price.

Several other analysts also recently commented on the company. HC Wainwright increased their price objective on Genmab A/S from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 2nd. Wolfe Research began coverage on Genmab A/S in a research report on Friday, March 27th. They set an “outperform” rating and a $32.00 target price on the stock. Weiss Ratings downgraded Genmab A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 8th. The Goldman Sachs Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research report on Wednesday, April 22nd. Finally, Truist Financial initiated coverage on Genmab A/S in a research note on Wednesday, May 27th. They set a “buy” rating and a $40.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $39.28.

Genmab A/S Trading Up 1.1%

GMAB opened at $29.17 on Wednesday. Genmab A/S has a fifty-two week low of $21.00 and a fifty-two week high of $35.43. The firm has a market capitalization of $18.19 billion, a PE ratio of 22.10, a P/E/G ratio of 1.83 and a beta of 0.84. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.18 and a quick ratio of 2.17. The company’s 50-day moving average is $26.77 and its 200 day moving average is $28.32.

Hedge Funds Weigh In On Genmab A/S

Hedge funds and other institutional investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC grew its stake in Genmab A/S by 124.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after purchasing an additional 1,174 shares during the period. Sei Investments Co. boosted its holdings in shares of Genmab A/S by 4.2% in the 2nd quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock worth $1,283,000 after buying an additional 2,496 shares during the last quarter. Squarepoint Ops LLC grew its position in Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after buying an additional 81,434 shares during the period. Quantinno Capital Management LP grew its position in Genmab A/S by 64.9% during the second quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock valued at $3,267,000 after buying an additional 62,226 shares during the period. Finally, Raymond James Financial Inc. increased its holdings in Genmab A/S by 48.1% during the second quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock worth $643,000 after buying an additional 10,113 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.